Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Mathew, Joseph L ^a,c   El Dib, Regina ^b   Mathew, Preethy J ^c   Boxall, Elizabeth H ^d   Brok, Jesper ^e  

^a Advanced Pediatrics Centre   (India)

^b MCMASTER UNIVERSITY   (Canada)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; DNA; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; CLINICAL TRIAL; CONVULSION; COST EFFECTIVENESS ANALYSIS; DEATH; DIARRHEA; DRUG FATALITY; ERYTHEMA; FEVER; FOLLOW UP; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION COMPLICATION; INFECTION RISK; INTRAHEPATIC BILE DUCT; LIVER CELL CARCINOMA; LIVER FAILURE; MALAISE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; SWELLING; SYSTEMATIC REVIEW; TREATMENT REFUSAL; VACCINATION;

EID: 55049128321     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006481.pub2     Document Type: Review

References (104)

1. Ambrosch 1992 {published data only} Ambrosch F, Andre FE, Delem A, D'Hondt E, Jonas S, Kunz C, et al.Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992;10(Suppl 1):S142-5.
2. Aristegui 1995 {published data only} Aristegui J, Muñiz J, Pérez Legorburu A, Imaz M, Arrate JP, Suárez MD, et al.Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine 1995;13(11):973-7.
3. Bassily 1995 {published data only} Bassily S, Kotkat A, Gray G, Hyams KC, Brown FM, Imam IZ, et al.Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. American Journal of Tropical Medicine and Hygiene 1995;53(4):419-22.
4. Coursaget 1984 {published data only} Coursaget P, Deciron F, Tortey E, Barin F, Chiron JP, Yvonnet B, et al.Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal). IARC Scientific Publications 1984;63:319-35.
5. Giammanco 1991 {published data only} Giammanco G, Li Volti S, Mauro L, Bilancia GG, Salemi I, Barone P, et al.Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991;9(10):747- 50.
6. Greenberg 1996 {published data only} Greenberg DP, Vadheim CM, Marcy SM, Partridge S, Jing J, Chiu CY, et al.Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA Vaccine Study Group. Vaccine 1996;14(8):811- 6.
7. Liao 1999 {published data only} Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al.Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999;17(20-21):2661-6.
8. Perrin 1986 {published data only} Perrin J, Coursaget P, Ntareme F, Chiron JP. Hepatitis B immunization of newborns according to a two dose protocol. Vaccine 1986;4(4):241-4.
9. Sun 1991 {published data only} Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, Zhen Y, et al.Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detection and Prevention 1991;15(4):313-8.
10. Tsega 1990 {published data only} Tsega E, Tafesse B, Nordenfelt E, Wolde-Hawariat G, Hansson BG, Lindberg J. Immunogenicity of hepatitis B vaccine simultaneously administered with the expanded programme on immunisation (EPI). Journal of Medical Virology 1990;32:232-5.
11. Wang 1985 {published data only} Wang YJ, Kang Y, Gong ZL, Mei YX, Xu JY, Meng LX, et al.Hepatitis B vaccine in neonates Induction of anti-HBs immune response and interruption of maternal HBsAg transmission. Chinese Medical Journal 1985;98(4):265-70.
12. Xueliang 2000 {published data only} * Xueliang W, Huiwen X, Guihua Z. Long-term efficacy and immunological memory of plasma-derived hepatitis B vaccine 11 years after initial inoculation. Journal of Xi'An Medical University, English Edition 2000;12(2): 122-5.
13. Xu H, Zhuang G, Wang X, Chen Q, Chen Z. Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization. Zhonghua yu fang yi xue za zhi (Chinese Journal of Preventive Medicine) 2000;34(2):113-5.
14. Xu H, Zuo H, Zhuang G. Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 1998;32(4):205-7.
15. Aach 1982 {published data only} Aach RD. Hepatitis prophylaxis. The Johns Hopkins Medical Journal 1982;151(6):318-25.
16. Abbas 1999 {published data only} Abbas R, Ahenad V. Evaluation of the immunogenicity of hepatitis B vaccine in students of the Isfahan university of medical sciences. Asian Pacific Journal of Allergy Immunology 1999;17 Suppl 1:25.
17. Abdurrahman 1984 {published data only} Abdurrahman MB. Hepatitis B infection and immunization: A review. Saudi Medical Journal 1984;5(4):369-76.
18. Akbar 1997 {published data only} Akbar SM, Kajino K, Tanimoto K, Kurose K, Masumoto T, Michitaka K, et al.Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. Journal of Hepatology 1997;26(1):131-7.
19. Akram 2005 {published data only} Akram DS, Maqbool S, Khan DS, Jafri R, Randhawa S, Valenzuela-Silva C, et al.Immunogenicity of a recombinant, yeast-derived, antihepatitis B vaccine after alternative dosage and schedule vaccination in Pakistani children. Vaccine 2005;23(50): 5792-7.
20. Alikasifoglu 2001 {published data only} Alikasifoglu M, Cullu F, Kutlu T, Arvas A, Tastan Y, Erginöz E, et al.Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates. Journal of Tropical Pediatrics 2001;47:60-2.
21. Ambrosch 1994 {published data only} Ambrosch F, Wiedermann G, André FE, Delem A, Gregor H, Hofmann H, et al.Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. Journal of Medical Virology 1994;44(4):452-6.
22. Artan 2004 {published data only} Artan R, Erol M, Velipasaoglu S, Yegin O. The effect of concurrent use of hepatitis B and Bacille Calmette-Guerin vaccination on antihepatitis B response. Saudi Medical Journal 2004;25(12):1939-42.
23. Assateerawatt 1993 {published data only} Assateerawatt A, Tanphaichitr VS, Suvatte V, Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, Gen-Hevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pacific Journal of Allergy Immunology 1993;11(1):85-91.
24. Ayoola 1984 {published data only} Ayoola EA. Hepatitis B vaccine in developing countries: problems and prospects. IARC Scientific Publications 1984;63:297-305.
25. Ayoola 1986 {published data only} Ayoola EA, Atoba MA, Johnson AO. Intradermal vaccination against hepatitis B virus infection in an endemic area (Nigeria), two year results. Archives of Virology 1986;91(3-4):291-6.
26. Baldy 2004 {published data only} Baldy JL, de Lima GZ, Morimoto HK, Reiche EMV, Matsuo T, de Mattos ED, et al.Immunogenicity of three recombinant hepatitis B vaccines administered to students in three different doses containing half the antigen amount routinely used for adult vaccination. Revista do Instituto de Medicina Tropical de Sao Paulo 2004;46(2):103-7.
27. Chunsuttiwat 1997 {published data only} Chunsuttiwat S, Biggs BA, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, et al.Integration of hepatitis B vaccination into the expanded programme on immunization in Chonburi and Chiangmai provinces, Thailand. Vaccine 1997;15(6-7): 769-74.
28. Coutinho 1983 {published data only} Coutinho RA, Lelie N, Albrecht-Van Lent P, Reerink-Brongers EE, Stoutjesdijk L, Dees P, et al.Efficacy of a heat inactivated hepatitis B vaccine inmale homosexuals: outcome of a placebo controlled double blind trial. BMJ (Clinical Research Ed.) 1983;286(6374):1305-8.
29. * Coutinho RA, Lelie PN, Albrecht-Van Lent P, Stoutjesdijk L, Huisman J, Kuipers H, et al.Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands. Developments in Biological Standardization 1983;54:287-92.
30. Duclos 2003 {published data only} Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. Journal of Hepatology 2003;39:S83-8.
31. Fortuin 1993 {published data only} Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, et al.Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunization. Lancet 1993;341(8853):1129-31.
32. Gomez 2002 {published data only} Gomez J, Vesga BE, Bucaramanga I. No English title [Eficacia de la vacunacin contra hepatitis B en trabajadores de la salud en un hospital colornbiano]. Acta Medica Colombiana 2002;27:103-7.
33. Guihua 1997 {published data only} Guihua Z, Huiwen X, Xueliang W, Hong Z, Pengbo L, Lingbin K, et al.Efficacy of plasma-derived hepatitis Bvaccine produced by China 9 years after initial injection. Journal of Xi'an Medical University, English Edition 1997;9(2):144-50.
34. Guihua 1998 {published data only} Guihua Z, Huiwen X, Hong Z, Xueliang W, Pengbo L, Lingbin K. Six-year efficacy of hepatitis Brevaccination: a double-blind, placebo-controlled and randomized field trial. Journal of Xi'an Medical University, English Edition 1998;10(1): 44-8.
35. Hall 1993 {published data only} Hall AJ. Hepatitis B vaccination: protection for how long and against what?. BMJ (Clinical Research Ed) 1993;307(6899):276-7.
36. Jones-Lecointe 2001 {published data only} Jones-Lecointe A, Swanston WM, Charles WP, Simeon D. Immunization status of thirty patients with sickle cell disease five years post hepatitis B vaccination. West Indian Medical Journal 2001;50(4):317-8.
37. Koff 1994 {published data only} Koff RS, Needles CF, Germanaud J, Barthez JP. Immunogenicity of hepatitis B vaccines. JAMA 1994;272(3):201-2.
38. Liao 1998 {published data only} Liao S, Li R, Li H, Yang J, Zeng X. Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1998;20(2):89-94.
39. Lok 2004 {published data only} Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127 Suppl 1:S303-9.
40. Margolis 1995 {published data only} Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization - an economic-analysis of current recommendations. JAMA 1995;274(15):1201-8.
41. Martins 2004 {published data only} Martins RM, Bensabath G, Arraes LC, Oliveira ML, Miguel JC, Barbosa GG, et al.Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Memórias do Instituto Oswaldo Cruz 2004;99(8):865-71.
42. Maupas 1976 {published data only} * Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, et al.Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1981;1(8215):289-92.
43. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Immunisation against hepatitis B in man. Lancet 1976;1(7974):1367-70.
44. Maupas 1981 {published data only} Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, et al.Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1981;1(8215):289-92.
45. Montesano 2002 {published data only} Montesano R. Hepatitis B immunization and hepatocellular carcinoma: the Gambia hepatitis intervention study. Journal of Medical Virology 2002;67(3):444-6.
46. Perrilo 1987 {published data only} Perrilo R, Bodicky C, Campbell C, Davis E, Veit H. A randomized, controlled-study of the recombinant yeast hepatitis-B vaccine in the mentally-retarded. Journal of Medical Virology 1987;21(4):A102-A3.
47. Perroni 1989 {published data only} Perroni L, Mattioli R, Ensoli G, Albertoni F, Duchini B, Ungaro P, et al.Vaccination against hepatitis B: 3 years' experience at the Latium Operative Unit [Vaccinazione contro l'epatite B: tre anni di esperienza presso l'Unità Operativa di Latina]. Annali di igiene : medicina preventiva e di comunità 1989;1(6):1307-15.
48. Petersen 1993 {published data only} Petersen KM, Bulkow LR, Mcmahon BJ, Zanis C, Getty M, Peters H, et al.Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatric Infectious Disease Journal 2004;23(7):650-5.
49. Phanuphak 1989 {published data only} Phanuphak P, Phanpanich T, Wongurai S, Sirivichayakul S, Sriwanthana B, Panmuong W, et al.Comparative immunogenicity study of four plasma-derived hepatitis B vaccines in Thai young adults. Vaccine 1989;7(3):253-6.
50. Pongpipat 1987 {published data only} Pongpipat D, Suvatte V, Assateerawatts A, Bhethraratt S. Active pre-exposure immunisation against hepatitis B virus: immunogenicity of hepatitis B vaccine in healthy Thai adults and children. Asian Pacific Journal of Allergy and Immunology 1987;5(1):63-5.
51. Ricciardi 1990 {published data only} Ricciardi G, Graziano G. Safety and immunogenicity of an anti-hepatitis-B vaccine obtained using the recombinant DNA technique: results of a longitudinal study in hospital personnel [Sicurezza ed immunogenicita di un vaccino anti-epatite B ottenuto con la tecnica del DNA-ricombinante: risultati di un'indagine longitudinale su personale ospedaliero]. Bollettino dell'Istituto Sieroterapico Milanese 1990;69(2):385-90.
52. Rodrigo 1992 {published data only} Escudero A, Gilabert MS, García F, Gonzalez R, del Olmo JA, Wassel AH, et al.Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine 1992;10(11):798-801.
53. Stevens 1985 {published data only} Stevens CE, Taylor PE, Rubinstein P. Safety of the hepatitis B vaccine. New England Journal of Medicine 1985;312(6):375-6.
54. Szmuness 1980 {published data only} Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al.Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. New England Journal of Medicine 1980;303(15):833-41.
55. Szmuness 1981 {published data only} Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al.Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States [Hepatitis B vaccine: darstellung der Wirksamkeit in einem kontrollierten lkinischen Versuch an einer Persobegruppe mit hohen Risikofaktoren in den Vereinigten Staaten]. Innere Medizin 1981;8:79-80.
56. Thanavala 2005 {published data only} Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, et al.Immunogenicity in humans of an edible vaccine for hepatitis B. Proceedings of the National Academy of Sciences of the United States of America 2005;102(9):3378-82.
57. Thies 2002 {published data only} Thies N. Universal neonatal immunization for Hepatitis B. Journal of Paediatric Child Health 2002;38(2):211-2.
58. Tong 2005 {published data only} Tong NK, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al.Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney International 2005;68(5):2298-303.
59. Turchi 1997 {published data only} Turchi MD, Martelli CM, Ferraz ML, Silva AE, Cardoso D das D, Martelli P, et al.Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine. Revista do Instituto de Medicina Tropical de Sao Paulo 1997;39(1):15-9.
60. Xu 1985a {published data only} Xu ZY, Francis DP, Liu CB, Purcell RH, Duan SC, Chen RJ, et al.Prevention of hepatitis B virus carriage of infants using HBV vaccine in Shanghai. Preliminary report of a randomized double-blind placebo-controlled trial. Chinese Medical Journal 1985;98(9):623-6.
61. Xu 1985b {published data only} Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, et al.Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76(5):713-8.
62. Xu 1992 {published data only} Xu H. Evaluation of long-term efficacy on plasma-derived hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 1992;13(6):362-5.
63. Xu 1993 {published data only} Xu HW, Li DS, Xu JW. Evaluation of long-term efficacy of inoculation of hepatitis B vaccine on subjects with isolated low level of anti-HBs. Journal of Xian Medical University 1993;14(4):335-9.
64. Xu 1995 {published data only} Xu H, Sui X, Men B. The efficacy of plasma-derived hepatitis B vaccine in the sixth year after initial injection. Journal of Xi'an Medical University 1995;16(4):368-71.
65. Yuen 2004 {published data only} Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clinical Gastroenterology and Hepatology 2004;2(10):941-5.
66. Yvonnet 1987 {published data only} Yvonnet B, Coursaget P, Leboulleux D, Barres JL, Fritzell B, Sarr G, et al.Low-dose hepatitis B vaccine immunisation in children. Lancet 1987; Vol. 1, issue 8525:169.
67. Zhuang 1998 {published data only} Zhuang G, Xu H, Zuo H, Wang X, Liu P, Kong L. Six-year efficacy of hepatitis B revaccination: A double-blind, placebo-controlled and randomized field trial. Journal of Xi'an Medical University 1998;10(1):44-8.
68. Aggarwal 2004 Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. BMJ (Clinical Research Ed.) 2004;329:1080- 6.
69. Altman 2003 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ (Clinical Research Ed.) 2003;326:219.
70. Beasley 1984 Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Seminars in Liver Disease 1984;4:113-21.
71. CDC 1999 Centers for Disease Control and Prevention. Recommendations to prevent hepatitis B virus transmission-United States, updated. MMWR. Morbidity and Mortality Weekly Report 1999;48:33-4.
72. Chan 1991 Chan CY, Lee SD, Tsai YT, Lo KJ. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were elicited by a plasma-derived vaccine. Vaccine 1991;9 Suppl A:765-7.
73. Chan 2004a Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
74. Chan 2004b Chan AW, Krleza-Jeric' K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 2004;171:735-40.
75. Chan 2005 Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ (Clinical Research Ed.) 2005;330:753.
76. Chen 1996 Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al.Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
77. Chen 2005 Chen W, Gluud C. Vaccines for preventing hepatitis B in healthcare workers. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD000100.pub3]
78. Furukawa 2007 Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007;297:468-70.
79. Gall 2001 Gall SA. Hepatitis B virus immunization today. Infectious diseases in obstetrics and gynecology 2001;9:63-4.
80. Gitlin 1997 Gitlin 1997. Hepatitis B: diagnosis, prevention, and treatment. Clinical chemistry 1997;43:1500-6.
81. Gluud 2007a Gluud C, Nikolova D, Klingenberg SL, Als-Nielsen B, D'Amico G, Davidson B, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2007, Issue 2. Art. No.: LIVER.
82. Gluud 2007b Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734-42.
83. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
84. Higgins 2006 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. The Cochrane Collaboration, 2006.
85. Hyams 1995 Hyams K C. Risk of chronicity following acute hepatitis B virus infection. Clinical Infectious Diseases 1995;20:992-1000.
86. ICH-GCP 1996 International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice. E6 (R1). ICH Harmonised Tripartite Guideline 1996.
87. Lee 2006a Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positivemothers. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI:10.1002/14651858.CD004790.pub2]
88. Lee 2006b Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ (Clinical Research Ed.) 2006;332(7537):328-36.
89. Liaw 1998 Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
90. Maddrey 2000 Maddrey WC. Hepatitis B: an important public health issue. Journal of Medical Virology 2000;61:362-6.
91. Mahoney 1999 Mahoney FJ. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clinical Microbiology Review 1999;12(2):351-66.
92. McMahon 1985 McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al.Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of carrier state. The Journal of Infectious Diseases 1985;151:599-603.
93. Moyer 1994 Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. American journal of preventive medicine 1994;10 Suppl:45-55.
94. Nystrom 2000 Nystrom RJ, Timmons AJ. Completion of hepatitis B vaccination series in school-based health centers. The Journal of Adolescent Health 2000;26:320-1.
95. Rehermann 2003 Rehermann B. Immune responses in hepatitis virus infection. Seminars in Liver Disease 2003;23:21-38.
96. RevMan 2003 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
97. Rizzetto 2002 Rizzetto M, Zanetti AR. Progress in the prevention and control of viral hepatitis B. Closing remarks. Journal of Medical Virology 2002;67:463-6.
98. Royle 2003 Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
99. Schroth 2004 Schroth RJ, Hitchon CA, Uhanova J, Noreddin A, Taback SP, Moffatt MEK, et al.Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI:10.1002/14651858.CD003775.pub2]
100. Van Damme 1997 Van Damme P, Kane M, Meheus A on behalf of the Viral Hepatitis Prevention Board. Integration of hepatitis Bvaccination into national immunisation programmes. BMJ (Clinical Research Ed.) 1997;314:1033.
101. Walsh 2001 Walsh K, Alexander GJM. Update on chronic viral hepatitis. Postgraduate Medical Journal 2001;77:498-505.
102. West 1993 West D J, Calandra G B, Hesley T M, Idoli V, Miller W J. Control of hepatitis B through routine immunization of infants: the need for flexible schedules, and new combination vaccine formulations. Vaccine 1993;11:S21-7.
103. WHO 2004 World Health Organisation. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/ (Accessed February 2007) 2004.
104. Wong 1994 Wong VK, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. The Pediatric Infectious Disease Journal 1994;13:936.